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Fisher's least significant diÂerence test. A value of P<0.05
Aluminium hydroxide was used to control phosphate (2-tailed) was regarded as significant. as necessary. This initial period was followed by withdrawal of aluminium hydroxide and reversion to an orthodox regimen comprising provision of suÃcient calcium carbonate to control serum phosphate and dialysate calcium at 1.25 mM, with the option to Results reduce to 0.6 mM in those patients becoming hypercalcaemic.
The conversion from dialysate calcium at 1.75 mM to 1.25 mM ( and by 9 months mean plasma phosphate (now controlled using calcium carbonate) did not diÂer sigThirty consecutive patients entering the CAPD programme nificantly from that at entry (1.66±0.44 vs were enrolled. After a 2-month run in using 1.75 mM calcium 1.59±0.47 mM, NS ).
dialysate and aluminium hydroxide, the subjects entered a Ionized calcium showed a small but highly significant 3-month phase of 1.25 mM dialysate with continuation of aluminium hydroxide as the sole phosphate binder. decrease from 1.17±0.06 to 1.11±0.08 mM (P= Subsequently the patients entered a final 9-month phase in 0.0004) following conversion from 1.75 to 1.25 mM which dialysate calcium remained at 1.25 mM and calcium calcium dialysate ( Figure 1 ). This change was seen in carbonate was substituted for aluminium hydroxide progress-nearly all the patients (20 of 22 ), and was not related ively, and titrated to achieve optimum phosphate control to changes in inorganic phosphate (r=0.27, P=0.22) with a target range of 1.00-1.75 mM. During this phase, or to PTH at entry (r=0.34, P=0.12). Parallel changes patients becoming hypercalcaemic had their dialysate calcium in serum total calcium were found (2.48±0.15 vs reduced further to 0.6 mM with the aim of allowing continua-2.38±0.14 mM, P<0.01). binder but in one patient partial reversion to alumiIonized calcium was measured in fresh whole blood using a nium hydroxide was necessary (Table 1 ) .
Ciba Corning 634 ISE Ca2+/pH Analyser (Ciba Corning Ionized calcium increased following introduction of Diagnostics Ltd, Halstead, Essex, UK ). The normal range calcium carbonate, reaching levels that were slightly (defined as mean±2 SD) in 42 healthy subjects was above those at entry ( 1.21±0.09 vs 1.17±0.06 mM, 1.16-1.28 mM. Samples for PTH and osteocalcin assays were P=0.047). Total calcium did not change significantly cooled and separated immediately, and then stored at −20°C (2.52±0.16 vs 2.48±0.15 mM, NS). These increases pending assay. Intact parathyroid hormone ( PTH) was measured in plasma using a 2-site immunoassay (Allegro, took ionized and total calcium to concentrations signiNicholls Institute, San Cupistrano, Ca). The normal range ficantly above the 3-month nadir (1.21±0.09 vs is 10-55 pg/ml with intra-assay CV of <7% and interassay 1.11±0.08 mM, P=0.0001 for ionized calcium and CV <5% over the range 10-1000 pg/ml. Osteocalcin was 2.52±0.16 vs 2.38±0.14 mM, P=0.0003 for total measured in plasma using a human osteocalcin immunoradi-calcium).
ometric assay (Nicholls Institute, San Cupistrano, Ca).
PTH, which at 3 months was significantly above Between batch precision was 6% at 12 ng/ml. baseline, decreased after the introduction of calcium carbonate, finally at 9 months reaching values indistinData presentation and analysis guishable from those at entry (entry value 259, range 11-1149 and 9 months value 305, range 7-1030 pg/ml, calcium represents a compromise, resulting in increased so, there is some evidence that when giving oral calcium risk of hyperparathyroidism if calcium intake is too carbonate, there is still a tendency for PTH to increase low (inadequate prescription or poor compliance) and in some patients [9 ] .
conversely in a risk of hypercalcaemia and unacThe observation that these patients' hyperparathyceptable increases of the Ca×Pi product in a minority roidism could be improved by the subsequent introducof patients. At these extremes there remains a need for tion of calcium carbonate is reassuring, and suggests a high-calcium dialysate (1.75 mM ) and a very lowthat the deterioration of hyperparathyroidism during calcium dialysate (0.6 mM or less), to allow suÃcient the early part of the protocol was the direct result of flexibility for optimum management. reduced calcium dialysate in combination with inadequate oral calcium intake, rather than being merely part of an underlying trend of worsening hyperparathy-References roidism [11 ] .
As in earlier studies of reduced calcium dialysate in 
